Akebia Therapeutics, Inc. (AKBA) stock intrinsic value fair value estimate & owner earnings analysis

Akebia Therapeutics sells two kidney-disease drugs in the United States: Auryxia (a phosphate binder for dialysis patients) and Vafseo (an oral anemia treatment launched in January 2025). In 2025 revenue was $236.2 million, of which Auryxia (including its authorized generic) was $181.5 million and Vafseo $45.8 million. Net loss was only $5.3 million, against $69.4 million the year before. How we measure earnings. 2025 operating cash flow was $68.0 million, but $48.5 million of that came from a jump in accrued expenses, mostly rebates owed on product sales (product rebates accrued rose from $6.1 million to $64.7 million). That is money collected but not yet paid, so we strip out the working-capital swing. After also charging stock compensation ($11.3 million) and capital spending ($0.3 million), 2025 owner earnings were about $39.9 million, or $0.155 per share. Prior years were negative (2024: -$0.068 per share; 2023: -$0.121; 2022: -$0.483). Because Vafseo's launch and Auryxia's loss of patent protection in March 2025 changed the business, only 2025 describes it today, and it is a single year. One more adjustment matters: cash flow adds back $21.8 million of non-cash interest, mostly on money owed to CSL Vifor as royalties on Vafseo. Those royalties are paid through financing activities (only about $5 million was paid in 2025), but they are a real, growing cost of selling Vafseo, so the cases below treat them as one. What has changed since. First-half 2026 revenue was $102.7 million versus $119.8 million a year earlier, and the company lost $18.0 million. Operating cash flow was -$17.7 million; after removing working-capital movements and stock compensation, owner earnings were roughly break-even to slightly negative (about -$2.6 million). Two quarters in a row now point below 2025's level, so we do not carry the $0.155 forward as the earning power. The key dated risk. Medicare's special add-on payment (TDAPA) that supports both Vafseo and Auryxia in dialysis clinics runs through the end of 2026. After that, neither drug receives a separate payment; clinics get a higher bundled rate instead, and the company itself states that without new legislation reduced reimbursement could limit clinic adoption of Vafseo. Separately, six generic makers are licensed to sell Auryxia generics since March 20, 2025; so far only an authorized generic is on the market, but Teva received tentative FDA approval on January 22, 2026. Growth check. Trailing owner earnings moved from -$14.4 million to +$39.9 million, but that swing came from the launch, rebate timing and a one-time change in business, not a repeatable rate. Our base case starts 2026 lower (about -$3 million), consistent with the first half; we found no dated, filed reason for a rebound and credit no growth from new products, share gains or the pipeline (praliciguat, AKB-097). Bear case (about -$0.15 per share). Generics take most of Auryxia, add-on payments end with nothing replacing them, and Vafseo sales stall after the add-on ends. Owner earnings are about -$5 million in 2026 and -$20 million in each of 2027 and 2028, with the $55 million BlackRock term loan maturing in January 2028 and floating-rate interest of 4.25% floor plus 6.75%. After 2028 nothing named supports any value. A negative figure means the operations consume more than they earn before counting the $184.8 million of cash held at December 31, 2025, which we do not add back. Base case (about $0.06 per share). Owner earnings of about -$3 million in 2026, then about $3 million a year from 2027 through 2036 from an established Vafseo and a shrinking Auryxia franchise after paying Vifor royalties, and nothing credited after 2036. The $3 million level is a judgement: well below 2025's $39.9 million and above the first-half 2026 pace, reflecting Vafseo's existing $45.8 million sales base and no growth. Bull case (about $0.60 per share). Auryxia erosion is slow because only one authorized generic is on the market and Teva has tentative rather than final approval, and Vafseo keeps growing under the higher bundled rate. Owner earnings recover to about $25 million a year (roughly 60 percent of 2025) from 2027 to 2036, with about $5 million in 2026. Debt and obligations. Term debt of $55 million, settlement royalties of $67.3 million, a $40 million working-capital fund repaid through 8 to 14 percent royalties on Vafseo sales, and $52 million tied to sold future royalties all rank ahead of shareholders. We do not subtract them from value because the earnings already bear the cash cost, but they are why the bear case is worse than zero. What would make this wrong. If Vafseo sales hold up after TDAPA ends, the bull case becomes likely; if Auryxia generics launch broadly in 2026 and clinics restrict Vafseo, the bear case applies. The latest quarterly report on file is for June 30, 2026, so the data are current. Because the base case is worth pennies per share and results could easily turn negative, the margin-of-safety price is well below base value.